WEBINAR TOMORROW
September 23, 2026
1 PM EST / 10 AM PST
I am excited to announce my upcoming webinar on peptide therapy, where we will take a practical look at the regulatory landscape, clinical applications, diagnostic considerations, patient selection, monitoring, and outcome driven prescribing.
Peptide therapy is evolving rapidly across metabolic health, regenerative medicine, hormone optimization, and other areas of clinical interest.
But responsible use requires more than knowing which peptides are available.
It requires an understanding of regulations, clinical applications, patient selection, diagnostics, safety, monitoring, and measurable outcomes.
This webinar will examine those areas through a practical, clinically focused framework.
WHAT WE WILL COVER
FDA Regulations
We will examine the evolving regulatory landscape surrounding peptide therapy and compounded medications.
Compounding And Product Sourcing
We will discuss the distinction between Research Use Only vendors and legitimate compounding pharmacies, and why product sourcing matters.
Diagnostics And Biomarkers
We will discuss the importance of appropriate evaluation and relevant laboratory testing before treatment.
Clinical Applications
We will examine potential clinical applications, patient selection, and considerations for appropriate use.
Safety And Monitoring
We will discuss contraindications, patient monitoring, and the importance of ongoing evaluation.
Outcome Driven Prescribing
We will examine how measurable outcomes can be used to determine whether a treatment strategy is producing the intended result.
DIAGNOSIS SHOULD COME BEFORE THE PEPTIDE
The question should not simply be:
“Which peptide should this patient take?”
The better question is:
“What clinical problem are we trying to address, and what evidence demonstrates that this patient has that problem?”
That requires appropriate evaluation, relevant laboratory testing, consideration of risk factors, and an understanding of the patient’s overall clinical picture.
OUTCOME DRIVEN PRESCRIBING
The goal should not simply be to put a patient on a peptide.
The goal should be to determine whether the intervention is producing a meaningful and measurable outcome.
That may include changes in laboratory markers, body composition, metabolic parameters, symptoms, functional measures, or other patient specific outcomes.
This creates a more disciplined approach:
Diagnosis
Treatment
Monitoring
Outcome
Clinical decision
MOVING BEYOND PEPTIDE HYPE
Peptide therapy has significant potential, but responsible implementation requires more than enthusiasm for new compounds.
It requires regulatory awareness.
It requires appropriate diagnosis.
It requires thoughtful patient selection.
It requires appropriate sourcing.
It requires patient monitoring.
And most importantly, it requires measurable outcomes.
The goal is to move away from peptide shopping and toward diagnosis driven, evidence informed care with measurable outcomes.
JOIN THE WEBINAR
September 23, 2026
1 PM EST / 10 AM PST
Register here:
EDUCATIONAL DISCLAIMER
I am not a physician, licensed medical provider, pharmacist, or attorney.
This article is provided for educational and informational purposes only and is not medical, legal, regulatory, or prescribing advice. Clinical and regulatory decisions should be independently evaluated by appropriately licensed professionals.
Anderson Triggs, MBA
0 Comments